These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 21629510)

  • 1. HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.
    Alfonso Y; Monzote L
    Open Med Chem J; 2011; 5():40-50. PubMed ID: 21629510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Highly Active AntiRetroviral Therapy and opportunistic protozoan infections].
    Pozio E
    Parassitologia; 2004 Jun; 46(1-2):89-93. PubMed ID: 15305694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of HIV-protease inhibitors on opportunistic parasites.
    Pozio E; Morales MA
    Trends Parasitol; 2005 Feb; 21(2):58-63. PubMed ID: 15664527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing morbidity of cutaneous diseases in patients with HIV after the introduction of highly active antiretroviral therapy including a protease inhibitor.
    Calista D; Morri M; Stagno A; Boschini A
    Am J Clin Dermatol; 2002; 3(1):59-62. PubMed ID: 11817969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Highly Active AntiRetroviral Therapy and cryptosporidiosis].
    Morales Gomez MA
    Parassitologia; 2004 Jun; 46(1-2):95-9. PubMed ID: 15305695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of integrase inhibitors vs protease inhibitors is associated with improved HIV viral suppression.
    Kleinmann WN; Pruszynski JE; Adhikari EH
    Am J Obstet Gynecol MFM; 2023 Nov; 5(11):101151. PubMed ID: 37689245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.
    Barry M; Mulcahy F; Merry C; Gibbons S; Back D
    Clin Pharmacokinet; 1999 Apr; 36(4):289-304. PubMed ID: 10320951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [HIV infection, antiretroviral therapy, and endothelium].
    Hürlimann D; Weber R; Enseleit F; Lüscher TF
    Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
    Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time to treatment disruption in children with HIV-1 randomized to initial antiretroviral therapy with protease inhibitors versus non-nucleoside reverse transcriptase inhibitors.
    Yin DE; Ludema C; Cole SR; Golin CE; Miller WC; Warshaw MG; McKinney RE;
    PLoS One; 2020; 15(11):e0242405. PubMed ID: 33226999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in national antiretroviral prescribing patterns between black and white patients with HIV/AIDS, 1996-2006.
    Oramasionwu CU; Brown CM; Lawson KA; Ryan L; Skinner J; Frei CR
    South Med J; 2011 Dec; 104(12):794-800. PubMed ID: 22089356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-related neuropathology, 1985 to 1999: rising prevalence of HIV encephalopathy in the era of highly active antiretroviral therapy.
    Neuenburg JK; Brodt HR; Herndier BG; Bickel M; Bacchetti P; Price RW; Grant RM; Schlote W
    J Acquir Immune Defic Syndr; 2002 Oct; 31(2):171-7. PubMed ID: 12394795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CMV retinitis in the era of HAART.
    Cassoux N; Bodaghi B; Katlama C; LeHoang P
    Ocul Immunol Inflamm; 1999 Dec; 7(3-4):231-5. PubMed ID: 10611732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections.
    Hung CC; Chang SC
    J Antimicrob Chemother; 2004 Nov; 54(5):849-53. PubMed ID: 15456733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.